A study on the synthesis of Erlotinib hydrochloride for lung cancer drug

Abstract

Erlotinib hydrochloride is a 4-anilinoquinazoline and an EGFR-tyrosine kinase inhibitor for treatment of non-small cell lung cancer. In this article, an inexpensive and easy method has been described for the synthesis of this compound. Erlotinib hydrochloride was synthesized in six steps starting from 3,4-dihydroxy benzaldehyde with 41.6% performance. The product and intermediates were characterized by IR, 1 H-NMR, 13C-NMR, MS spectra and the purity of the product was determined by HPLC.